Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial-Reference-Cited by-同舟云学术

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial

Published:2019-12-18 Issue:6 Volume:126 Page:1175-1182
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Papakonstantinou Antroula¹^ORCID,Matikas Alexios¹,Bengtsson Nils Olof²,Malmström Per³⁴,Hedayati Elham¹,Steger Guenther⁵⁶,Untch Michael⁷,Hübbert Laila⁸⁹,Johansson Hemming¹,Hellström Mats¹,Gnant Michael¹⁰,Loibl Sibylle¹¹,Greil Richard¹²¹³^ORCID,Moebus Volker¹⁴,Foukakis Theodoros¹,Bergh Jonas¹

Affiliation:

1. Department of Oncology-Pathology Karolinska Institute and University Hospital Stockholm Sweden

2. University Hospital Umeå Umeå Sweden

3. Division of Oncology and Pathology Department of Clinical Sciences Lund University Lund Sweden

4. Department of Hematology, Oncology, and Radiation Physics Skåne University Hospital Lund Sweden

5. Medical Oncology Medical University of Vienna Vienna Austria

6. Gaston H. Glock Research Center Medical University of Vienna Vienna Austria

7. Department of Obstetrics and Gynecology Helios Hospital Berlin‐Buch Berlin Germany

8. Department of Medical and Health Sciences, Division of Cardiovascular Medicine Linkoping University Linkoping Sweden

9. Transplant Institute Sahlgrenska University Hospital Gothenburg Sweden

10. Department of Surgery Medical University of Vienna Vienna Austria

11. German Breast Group Neu‐Isenburg Germany

12. Third Medical Department Paracelsus Medical University Salzburg Austria

13. Salzburg Cancer Research Institute, Cancer Cluster Salzburg Salzburg Austria

14. Department of Medicine II, Hematology & Oncology Goethe University of Frankfurt Frankfurt Germany

Funder

Amgen

Radiumhemmets Forskningsfonder

Cancerfonden

Roche

Stockholms Läns Landsting

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32653

Reference29 articles.

1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

2. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

3. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?

4. Trastuzumab containing regimens for early breast cancer;Moja L;Cochrane Database Syst Rev,2012

5. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper;Clinical Breast Cancer;2023-10

2. Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy;Molecular Oncology;2023-04-24

3. The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer;npj Breast Cancer;2023-04-21

4. Novel 5-Fluorouracil Carbonate-Loaded Liposome: Preparation, In Vitro, and In Vivo Evaluation as an Antitumor Agent;Molecular Pharmaceutics;2022-06-22

5. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial;British Journal of Cancer;2022-05-24